01—Abstract
Summary
Summary of the 10-Q filed May 6, 2024. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. (IFF) reported first-quarter 2024 net sales of $2.899 billiona, down from $3.027 billion in the prior-year period, a decrease the company attributes primarily to the divestitures of portions of the Savory Solutions and Flavor Specialty Ingredients businesses, partly offset by volume and price increases.
Operating profit rose to $199 millionb from $131 million, and net income attributable to IFF shareholders was $60 million, or $0.23 per diluted share, compared with a net loss of $9 million, or $(0.04) per share, a year earlier. Gross margin improved to 35.3% from 31.8%, and interest expense fell to $83 million from $100 million due to lower debt outstanding. Segment Adjusted Operating EBITDA totaled $578 million versus $503 million, with Scent and Health & Biosciences showing the strongest gains, while Pharma Solutions declined.
Cash flow from operations was $99 millionc compared with $127 million a year earlier, reflecting higher working capital, largely in receivables and inventories. Total debt was $10.298 billion at March 31, 2024, and cash and cash equivalents were $732 million. The company completed the divestiture of its Cosmetic Ingredients business on April 2, 2024, with gross cash proceeds of approximately $841 million, and agreed on March 19, 2024 to sell its Pharma Solutions business for up to $2.85 billion, with closing expected in the second quarter of 2025.
Under the financial covenant relief period, the company is restricted to cash dividends of no more than $0.81d per share per quarter and cannot repurchase shares. The filing also discloses ongoing investigations by the European Commission, the UK Competition and Markets Authority, the U.S. Department of Justice, and the Swiss Competition Commission into the fragrance businesses, with first-quarter legal and regulatory costs of $35 million recorded in the segment reconciliation. The company states it is unable to predict the duration or outcome of these investigations or whether they will materially affect its results.
02—Key points
Key Highlights
- Net sales were $2.899 billion, down from $3.027 billion, with the decline driven mainly by divestitures; currency neutral sales decreased 1%.
- Net income attributable to IFF shareholders was $60 million ($0.23 per diluted share), compared with a net loss of $9 million ($(0.04) per share) in the prior-year quarter.
- Gross margin rose to 35.3% from 31.8%, and operating profit increased to $199 million from $131 million.
- Segment Adjusted Operating EBITDA was $578 million versus $503 million, led by Scent ($157 million vs. $105 million) and Health & Biosciences ($159 million vs. $131 million).
- Cash flow from operating activities was $99 million versus $127 million, mainly due to higher receivables and inventories.
- Cosmetic Ingredients divestiture closed April 2, 2024 for gross cash proceeds of about $841 million; the Pharma Solutions sale for up to $2.85 billion is expected to close in Q2 2025.
- Total debt was $10.298 billion at March 31, 2024, and the company was in compliance with its financial covenants, with a net debt to credit adjusted EBITDA ratio of 4.42 to 1.0.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, International Flavors & Fragrances kept $0.02.
- Revenue$2.90B100.0%
- Cost of revenue−$1.88B64.7%
- Gross profit$1.02B35.3%
- Operating costs−$825.0M28.5%
- Operating income$199.0M6.9%
- Interest, other & tax−$139.0M4.8%
- Net income$60.0M2.1%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 6, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $2.90B$3.03B | −4.2% |
| Cost of Revenue | $1.88B$2.06B | −9.1% |
| Gross Profit | $1.02B$964.00M | +6.2% |
| R&D Expenses | $166.00M$161.00M | +3.1% |
| SG&A Expenses | $490.00M$454.00M | +7.9% |
| Operating Income | $199.00M$131.00M | +51.9% |
| Interest Expense | $83.00M$100.00M | −17.0% |
| Net Income | $60.00M-$8.00M | +850.0% |
| EPS (Basic) | $0.23$-0.04 | +675.0% |
| EPS (Diluted) | $0.23$-0.04 | +675.0% |
| Shares Outstanding (Basic) | 255.00M255.00M | 0.0% |
| Shares Outstanding (Diluted) | 256.00M255.00M | +0.4% |
05—Questions
Frequently Asked Questions
Why did net sales decline year over year?
Net sales fell $128 million, or 4% on a reported basis, to $2.899 billion. The filing attributes the decline mainly to approximately $153 million of impact from divestitures of portions of the Savory Solutions business and the Flavor Specialty Ingredients business, partly offset by volume and price increases. Exchange rate variations had an unfavorable impact of 3%.
How did profitability change in the quarter?
Gross profit increased $60 million to $1.024 billion, and operating profit rose to $199 million from $131 million. Restructuring charges fell to $3 million from $52 million, and interest expense decreased to $83 million from $100 million. The effective tax rate was 47.0%, compared with 157.1% in the prior-year period.
What are the company's main liquidity considerations?
Cash and cash equivalents were $732 million at March 31, 2024. Operating cash flow was $99 million, and dividends paid totaled $207 million. The company had $250 million drawn under its $2.000 billion Revolving Credit Facility and $836 million of commercial paper outstanding. Covenant amendments restrict share repurchases and limit cash dividends to $0.81 per share per quarter through the relief period.
What are the pending divestitures and their expected effects?
The Cosmetic Ingredients business sale closed on April 2, 2024, with gross cash proceeds of approximately $841 million, subject to closing adjustments. The Pharma Solutions business sale, valued at up to $2.85 billion, was agreed on March 19, 2024 and is expected to close in the second quarter of 2025. The filing states the Cosmetic Ingredients sale does not constitute a strategic shift and does not qualify as discontinued operations.
What legal and regulatory risks are disclosed?
The company is cooperating with investigations by the European Commission, the UK Competition and Markets Authority, the U.S. Department of Justice, and the Swiss Competition Commission into potentially anticompetitive conduct in its fragrance businesses. Several putative class actions have been filed in Canada and the United States. The company states it cannot predict the duration or outcome of these matters. Regulatory costs were $35 million in the quarter, primarily legal fees and provisions for the investigations.
06—Continue